Does IRAP contribute to Alzheimer's Disease Pathology?

IRAP 是否有助于阿尔茨海默病病理学？

• 批准号: nhmrc : 1047277
• 负责人: A/Pr Siew Yeen Chai
• 金额: $ 49.55万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/does-irap-contribute-disease-pathology/111925
• 关键词: Does; IRAP; contribute; Alzheimer; Disease

Alzheimer’s disease is a progressive brain disease which is results in memory loss and cell death. All currently prescribed drugs treat the memory loss but are unable to stop the deterioration of brain cells. We have developed a class of drugs that reverse memory loss. These drugs target a protein called insulin-regulated aminopeptidase, IRAP. We recently found that these drugs also reduce the disease pathology. This research proposal aims to investigate the role of IRAP in the initiation or progression of Alzheimer’s disease pathology.

阿尔茨海默氏病是一种渐进性脑部疾病，导致记忆丧失和细胞死亡。目前所有处方药都能治疗记忆丧失，但无法阻止脑细胞的退化。我们已经开发出了一类可以逆转记忆丧失的药物。这些药物靶向一种称为胰岛素调节氨基肽酶（IRAP）的蛋白质。我们最近发现，这些药物也减少了疾病的病理。本研究旨在探讨IRAP在阿尔茨海默病病理学发生或发展中的作用。